Bioventus Q3 2022 Earnings Report
Key Takeaways
Bioventus announced it has filed a Form 12b-25 for its Q3 2022 report, requiring more time to assess a potential non-cash impairment charge between $185 million and $205 million and to resolve a revised invoice for rebate claims from a large private payer. The company's management has concluded that its internal controls related to the timely recognition of quarterly rebates were inadequate.
Filed Form 12b-25 for late filing of Q3 2022 report.
Requires additional time to assess a potential non-cash impairment charge between $185 million to $205 million.
Seeking resolution on a revised invoice for rebate claims from a large private payer.
Management concluded that internal controls related to the timely recognition of quarterly rebates were inadequate.